Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan in Multiple Myeloma
NCT02811822Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Jun 2016
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of uproleselan in multiple myeloma (MM), sponsored by GlycoMimetics. Primary endpoints: Safety assessed by frequency, severity and relatedness of AEs at 6 months and Overall Response Rate at 18 months. Started Jun 2016; status: completed.
02
Drugs
uproleselan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02811822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811822.